200 filings
Page 3 of 10
8-K
t7clgx9efvv8
8 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
UPLOAD
5or9dm3t8yhb da5r1g9
6 Jun 23
Letter from SEC
12:00am
CORRESP
z4pqrkzxba8qoodl
6 Jun 23
Correspondence with SEC
12:00am
DEFA14A
1hv0vlf8o
15 May 23
Additional proxy soliciting materials
3:36pm
8-K
cg5aesp3vaf2qd3d
15 May 23
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
7:53am
8-K
sc20ymcg9zk5p4ih
5 May 23
Unregistered Sales of Equity Securities
9:00am
ARS
s110mfq
1 May 23
Annual report to shareholders
4:10pm
DEFA14A
xho6e9ys8r93i2iif
1 May 23
Additional proxy soliciting materials
4:06pm
8-K
8ph31yl8ebr0qaky1d
25 Apr 23
Submission of Matters to a Vote of Security Holders
4:01pm
S-8
ub0dal14i431 pvtq
29 Mar 23
Registration of securities for employees
5:01pm
8-K
o9p7j
29 Mar 23
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
7:45am
D
7jgiihjc
3 Mar 23
$7.48 mm in equity / options, sold $1.46 mm, 10 investors
4:09pm
8-K
6e4l3w 7e25
27 Feb 23
Entry into a Material Definitive Agreement
5:10pm
8-K
7oef0vg47565kq0fz2ea
22 Feb 23
Revolutionizing the treatment of Cystic Fibrosis through our unique BOLT Phage therapy platform Investor Presentation / Jan 2023
3:05pm